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Introduction 
The role of cholinergic bronchomotor tone may be 
magnified in circumstances which influence airway 
calibre adversely. Effective cholinergic blockade may, 
consequently, be of value in patients whose disease is 
manifested by decline in airway calibre (1). This is 
particularly true in chronic obstructive pulmonary 
disease (COPD) patients, because airway narrowing 
in asthma is due to more factors than vagal tone 
alone, whereas vagal tone may be the only reversible 
element in COPD (2). 
Although present anti-cholinergics often appear to 
be of greater efficacy than P-agonists in COPD, 
owing to their prolonged duration of broncho- 
dilation, their onset of action may be slower (2). It is 
not a surprise, therefore, that a number of clinical 
studies have shown the benefit of adding a P-agonist 
to anti-cholinergics such as ipratropium in COPD 
(3). 
The introduction of long-acting P-agonist 
bronchodilators gives physicians additional thera- 
peutic options for COPD, but their place in COPD 
treatment is currently not known. In any case, 
salmeterol appears to be more effective than sal- 
butamol in patients with stable COPD (4). It also 
provides more sustained bronchodilation and slower 
onset of action than ipratropium (5). 
The present study was designed to answer the 
question whether combined administration of 
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salmeterol and ipratropium, at the standard doses 
currently recommended in the marketing of these 
agents, would result in greater bronchodilation in 
patients with COPD than the use of either drug 
alone. 
Patients and Methods 
Twelve male patients with COPD, but in a stable 
phase of the disease, participated in the study after 
giving their informed consent. All fulfilled the criteria 
proposed by the American Thoracic Society (6). They 
were required to have a smoking history of more than 
10 pack-years and to be 40 years of age or older. 
Patients had a FEV, between 16 and 62% of 
predicted values after long-acting and short-acting 
bronchodilator drugs had been withheld for 24 h and 
12 h, respectively. A bronchodilator response prior to 
entry into the study was not required. Patients with a 
history of asthma, allergic rhinitis or atopy, or with a 
total blood eosinophil count over 400 mm- 3 were 
excluded. 
The study was performed using a single-blind, 
balanced, cross-over, randomized design and was 
conducted on four non-consecutive days. The four 
treatments were: (1) salmeterol hydroxynaphthoate 
(Glaxo, Verona, Italy) (50 pug, 25 pg inhalation - ‘) 
plus placebo (two inhalations); (2) ipratropium 
bromide (Boehringer Ingelheim, Florence, Italy) 
(4Opg, 2Opg inhalation ~ ‘) plus placebo; (3) 
salmeterol (5Opg) plus ipratropium (40,~g); and (4) 
placebo plus placebo. Drugs were all inhaled from 
a metered dose inhaler and holding chamber 
(AeroChamber) with mouthpiece. 
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Fig. I Mean percentage (f SE) changes in FEV, from 
baseline at different times after inhalation of salmeterol (0), 
ipratropium bromide (A), salmeterol+ipratropium 
bromide (U), or placebo (0). 
Lung function was controlled before drug admin- 
istration and 15, 30, 60, 120, 180, 240, 300, 360, 480, 
600 and 720 min thereafter. On each occasion, three 
measurements were taken, the highest value was 
used, and the bronchodilator response was expressed 
as percentage change from the initial value obtained 
on each day. 
As an expression of the total effect of each treat- 
ment, the areas under the FEV, response-time curves 
(AUC) were calculated for each patient. 
Statistical analysis was performed using one-way 
analysis of variance and Newman-Keuls test. The 
level of statistical differences was adjusted for the 
number of time intervals at which tests were done. 
The areas under the FEV, response-time curves were 
analysed by the trapezoidal rule. 
Results 
All patients completed the 4-day study. There were 
no significant differences between the baseline spiro- 
metric values of the four treatment groups (BO.05). 
The mean percent FEV, changes from control 
baseline values for each active treatment and placebo 
are shown in Fig. 1. 
Fifteen minutes after drug inhalation, the percent- 
age modification (mean & SE) induced by salmeterol 
(13.5% & 2.9) was smaller than that caused by 
ipratropium (19.3% & 4.6) and the combined treat- 
ment (16.1% & 3.2), but there was no significant 
difference between the three treatments (BO.05). 
The peak response (28.8% * 5.0) for salmeterol 
was greater than for ipratropium (26.0% f 9.1), but 
equivalent peak bronchodilatation occurred with sal- 
meter01 and salmeterol plus ipratropium (28.0 & 4.2). 
All active treatments produced a significant bron- 
chodilation effect from 15 to 360 min, when com- 
pared to placebo (P<O.O5), but only salmeterol and 
salmeterol plus ipratropium induced a signifi- 
cant (PcO.05) spirometric increase over the 12-h 
monitoring period. 
The mean (&SE) AUC,-,,,s for all patients 
were 2.67 1 f 0.55 for salmeterol, 1.061& 0.46 for 
ipratropium, and 2.71 l& 0.47 for salmeterol plus 
ipratropium. All AUC,-,,,s for active treatments 
were significantly greater than for placebo (WO.05) 
and that for salmeterol and salmeterol plus 
ipratropium were significantly (WO.05) greater than 
that for ipratropium alone. There was no significant 
difference (P10.05) between the salmeterol and 
salmeterol plus ipratropium AU&,,,s. 
Discussion 
These findings confirm that 50 pg salmeterol has a 
longer duration of action than 40 pg ipratropium in 
patients with stable COPD (5). These data also 
indicate clearly that ipratropium at the clinical 
recommended dose does not bring any further 
bronchodilation than has been achieved with 
salmeterol alone, although the onset of action after 
the combination of the two drugs may be faster than 
after salmeterol alone. 
It is conceivable that the subjects studied in this 
specific clinical situation were at the top of their 
bronchodilation response curve after inhalation of 
salmeterol. 
In any case, the results of the present study 
apparently contradict the assertion that vagal tone is 
the only dominant reversible element in patients with 
COPD. However, it is important to emphasize that 
P-agonists may also modulate neurotransmission in 
airways via prejunctional receptors on airway nerves 
(7). In human trachea and bronchi, P-agonists 
modulate cholinergic neurotransmission in vitro 
via prejunctional &receptors on postganglionic 
cholinergic nerves, and evidence has been given for 
P-adrenoceptor-mediated inhibition of cholinergic 
transmission in humans (8,9). It has also been dem- 
onstrated that P-agonists have an inhibitory effect on 
the firing of the tracheal parasympathetic ganglion 
cells (10). Furthermore, selective &agonists relax the 
tissue when tone is induced by electrical stimulation 
(8,11), but they have a short duration of action. On 
the contrary, salmeterol, which is intrinsically long 
acting, elicits a long-lasting inhibition of vagally 
stimulated airways contractions (12). 
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This information and the results of the present 
study suggest that salmeterol should induce 
bronchodilation not only because it activates 
&adrenoceptors, but also because it is effective in 
inhibiting cholinergic neurotransmission. Obviously, 
against this background of bronchodilation, clinical 
doses of ipratropium produce no further benefit. 
However, it must be stressed that the dose of 
ipratropium needed to produce near maximal 
bronchodilation is several times higher than the 
customary dosage (13). Therefore, the full therapeu- 
tic (and also safety) potential of combined salmeterol 
plus ipratropium can only be established using doses 
higher than those currently recommended in the 
marketing of these agents. 
Taking into account the authors’ recent (4,5,14) 
and present findings, it is believed that salmeterol 
alone has a place in the treatment of patients with 
COPD, that it should be considered an attractive 
alternative to other bronchodilators, and endorsed as 
first-line agent. Nevertheless, more detailed informa- 
tion about the functional consequences of regular use 
of this drug is now needed. 
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